Abstract
Dystonia is one of the most prevalent movement disorders, characterized by significant clinical and etiological heterogeneity. Despite considerable heritability (∼25%) and the identification of several disease-linked genes, the etiology in most patients remains elusive. Moreover, understanding the correlations between clinical manifestation and genetic variants has become increasingly complex.
To comprehensively unravel dystonia’s genetic spectrum, we performed exome sequencing on 1,924 dystonia patients [40.3% male, 92.9% White, 93.2% isolated dystonia, median age at onset (AAO) 33 years], including 1,895 index patients, who were previously genetically unsolved. The sample was mainly based on two dystonia registries (DysTract and the Dystonia Coalition). Further, 72 additional patients of Asian ethnicity, mainly from Malaysia, were also included. We prioritized patients with negative genetic prescreening, early AAO, positive family history, and multisite involvement of dystonia. Rare variants in genes previously linked to dystonia (n=405) were examined. Variants were confirmed via Sanger sequencing, and segregation analysis was performed when possible.
We identified 137 distinct likely pathogenic or pathogenic variants (according to ACMG criteria) across 51 genes in 163/1,924 patients [42.9% male, 85.9% White, 68.7% isolated dystonia, median AAO 19 years]. This included 153/1,895 index patients, resulting in a diagnostic yield of 8.1%. Notably, 77/137 (56.2%) of these variants were novel, with recurrent variants in EIF2AK2, VPS16, KCNMA1, and SLC2A1, and novel variant types such as two splice site variants in KMT2B, supported by functional evidence. Additionally, 321 index patients (16.9%) harbored variants of uncertain significance in 102 genes. The most frequently implicated genes included VPS16, THAP1, GCH1, SGCE, GNAL, and KMT2B. Presumably pathogenic variants in less well-established dystonia genes were also found, including KCNMA1, KIF1A, and ZMYND11. At least six variants (in ADCY5, GNB1, IR2BPL, KCNN2, KMT2B, and VPS16) occurred de novo, supporting pathogenicity. ROC curve analysis indicated that AAO and the presence of generalized dystonia were the strongest predictors of a genetic diagnosis, with diagnostic yields of 28.6% in patients with generalized dystonia and 20.4% in those with AAO < 30 years.
This study provides a comprehensive examination of the genetic landscape of dystonia, revealing valuable insights into the frequency of dystonia-linked genes and their associated phenotypes. It underscores the utility of exome sequencing in establishing diagnoses within this heterogeneous condition. Despite prescreening, presumably pathogenic variants were identified in almost 10% of patients. Our findings reaffirm several dystonia candidate genes and expand the phenotypic spectrum of some of these genes to include prominent, sometimes isolated dystonia.
Competing Interest Statement
K.E.Z. has received research support from Strathmann and the German Research Council. She reports speaker's honoraria from Bayer Vital GmbH, BIAL, AbbVie, Alexion, Allergan, and Merz outside the submitted work. She has served as a consultant and received fees from Merz, Ipsen, Alexion, Bial, and the German Federal Institute for Drugs and Medical Devices (BfArM). J.S.P. has research support RF1NS075321, RO1NS134586, RO1NS103957, NS107281, NS097437, U54NS116025, U19NS110456, NS097799, R33AT010753, RO1NS118146, NS124738, R01AG065214, NS124789, R21NS133875, R21TR004422, R21TR005231. Foundation support: Michael J. Fox Foundation, Barnes-Jewish Hospital Foundation (Elliot Stein Family Fund and Parkinson disease research fund), American Parkinson Disease Association (APDA) Advanced Research Center at Washington University, Missouri Chapter of the APDA, Paula and Rodger Riney Fund, Jo Oertli Fund, Huntington Disease Society of America, Murphy Fund, Fixel Foundation, N. Grant Williams Fund, Pohlman Fund, CHDI, and Prilenia. He is also co-director for the Dystonia Coalition, which has received the majority of its support through the NIH (grants NS116025, NS065701 from the National Institutes of Neurological Disorders and Stroke, TR001456 from the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences). R.L.B. performs botulinum toxin injections at the University of Rochester (50% effort); serves/has served on the scientific advisory board for Allergan, Ipsen, Merz, and Revance; receives research support from the Fox Foundation and the NIH (NINDS, ORDR): Dystonia Coalition Projects, Site PI; serves as a consultant and research study rater for AbbVie/Allergan; holds stock options in VisualDx; and serves/has served as an expert witness in legal proceedings including malpractice, not involving commercial entities. J.V. has received consultancies from Medtronic, Boston Scientific, Ceregate, and Newronika. He has served on advisory boards for Medtronic and Boston Scientific. He reports speaker's honoraria from Medtronic, Boston Scientific, Abbott, AbbVie, Bial, and Zambon outside the submitted work. H.A.J. has active or recent grant support (recent, active, or pending) from the US government (NIH), private philanthropic organizations (Cure Dystonia Now, Lesch-Nyhan Syndrome Children's Research Foundation), and industry (AbbVie, Addex, Aeon, Sage, Ipsen, Jazz). H.A.J. has also served on advisory boards or as a consultant for the NIH (CREATE Bio DSMB) and industry (AbbVie, Addex, Ipsen, Merz, and Vima). He has received stipends for administrative work from the International Parkinson's Disease and Movement Disorders Society. H.A.J. has also served on the Scientific Advisory Boards for several private foundations (Benign Essential Blepharospasm Research Foundation, Dystonia Medical Research Foundation). He also is principal investigator for the Dystonia Coalition, which has received the majority of its support through the NIH (NS116025, NS065701 from the National Institutes of Neurological Disorders and Stroke, TR001456 from the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences). C.Kl. has served as a medical advisor to Centogene, Retromer Therapeutics, Takeda, and Lundbeck and has received speaker's honoraria from Bial and Desitin. C.Ka. reports serving on advisory boards for Biogen and Roche outside of the submitted work. The other authors report no competing interests.
Funding Statement
This study was funded by the German Research Foundation (DFG, LO1555/10-1) and received additional support from the Dystonia Coalition through grants from the US National Institutes of Health (NS116025, NS067501, and TR001456). Furthermore, the DFG Research Infrastructure NGS_CC (project 407495230) contributed to this work as part of the Next Generation Sequencing Competence Network (project 423957469), with sequencing carried out at the Competence Centre for Genomic Analysis in Kiel, Germany. The University of Malaya Parkinson's Disease and Movement Disorders Research Program (PV035-2017) was awarded to A.H.T. and S.Y.L. M.M. and H.B. acknowledge funding through the DFG Excellence Initiative Strategy EXC 2167-390884018.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the University of Luebeck, Germany, gave ethical approval for this work (04-180, 05-030).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Raw data were generated at the Competence Centre for Genomic Analysis in Kiel, Germany, and are available from the corresponding author on request.
